% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kayser:130805,
      author       = {S. Kayser$^*$ and J. Krzykalla$^*$ and M. A. Elliott and K.
                      Norsworthy and P. Gonzales and R. K. Hills and M. R. Baer
                      and Z. Ráčil and J. Mayer and J. Novak and P. Žák and T.
                      Szotkowski and D. Grimwade and N. H. Russell and R. B.
                      Walter and E. H. Estey and J. Westermann and M. Görner and
                      A. Benner$^*$ and A. Krämer$^*$ and B. D. Smith and A. K.
                      Burnett and C. Thiede and C. Röllig and A. D. Ho and G.
                      Ehninger and R. Schlenk$^*$ and M. S. Tallman and M. J.
                      Levis and U. Platzbecker},
      title        = {{C}haracteristics and outcome of patients with
                      therapy-related acute promyelocytic leukemia front-line
                      treated with or without arsenic trioxide.},
      journal      = {Leukemia},
      volume       = {31},
      number       = {11},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-05883},
      pages        = {2347 - 2354},
      year         = {2017},
      abstract     = {Therapy-related acute promyelocytic leukemia (t-APL) is
                      relatively rare, with limited data on outcome after
                      treatment with arsenic trioxide (ATO) compared to standard
                      intensive chemotherapy (CTX). We evaluated 103 adult t-APL
                      patients undergoing treatment with all-trans retinoic acid
                      (ATRA) alone (n=7) or in combination with ATO (n=24), CTX
                      (n=53), or both (n=19). Complete remissions were achieved
                      after induction therapy in $57\%$ with ATRA, $100\%$ with
                      ATO/ATRA, $78\%$ with CTX/ATRA, and $95\%$ with
                      CTX/ATO/ATRA. Early death rates were $43\%$ for ATRA, $0\%$
                      for ATO/ATRA, $12\%$ for CTX/ATRA and $5\%$ for
                      CTX/ATO/ATRA. Three patients relapsed, two developed
                      therapy-related acute myeloid leukemia and 13 died in
                      remission including seven patients with recurrence of the
                      prior malignancy. Median follow-up for survival was 3.7
                      years. None of the patients treated with ATRA alone survived
                      beyond one year. Event-free survival was significantly
                      higher after ATO-based therapy $(95\%,$ $95\%$ CI,
                      $82-99\%)$ as compared to CTX/ATRA $(78\%,$ $95\%$ CI,
                      $64-87\%;$ P=0.042), if deaths due to recurrence of the
                      prior malignancy were censored. The estimated 2-year overall
                      survival in intensively treated patients was $88\%$ $(95\%$
                      CI, $80-93\%)$ without difference according to treatment
                      (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and
                      leads to better outcomes as compared to CTX/ATRA in t-APL.},
      cin          = {G330 / C060 / G040},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G040-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28322237},
      doi          = {10.1038/leu.2017.92},
      url          = {https://inrepo02.dkfz.de/record/130805},
}